YOU SEARCHED BY...
SEARCH BY...
Contract Service Directory
Contract Service Directory
CNS Contract Research
Company Headquarters
550 University Ave
NRC Bldg. Suite 508
Charlottetown, PE C1A 4P3
Canada
Contract Service Directory
Related Content
-
Breaking News | Collaborations & Alliances | Drug Discovery
Metrion, LifeArc Extend Neuroscience Alliance
Collaboration extended for another 12 months after successfully progressing into late stage hit-to-lead optimization phase.Contract Pharma Staff 01.18.21
-
Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Cyclolab and EpiPharma Form Joint Venture
Will develop and commercialize Peptide drug candidates for the treatment of debilitating CNS and Pulmonary diseases.Contract Pharma Staff 01.11.21
-
Breaking News | Collaborations & Alliances | Industry News
Angelini Pharma Acquires Arvelle Therapeutics for $960M
Angelini to become a leader in CNS and mental health disorder treatments; opening direct affiliates in France, UK, Nordics and Switzerland by 2022.Contract Pharma Staff 01.05.21
-
Bioanalytical Services | Breaking News | cGMP Manufacture | Industry News
Passage Bio Invests in Gene Therapy Manufacturing R&D Site
In combination with dedicated cGMP suite at Catalent, the new lab creates foundation for integrated AAV gene therapy manufacturing.Contract Pharma Staff 12.17.20
-
Breaking News | cGMP Manufacture | Industry News
Passage Bio, Catalent Begin cGMP Mfg. for Gene Therapies
Completion of dedicated cGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS product candidates.Contract Pharma Staff 12.10.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Clinical Trial Materials | Collaborations & Alliances | Industry News
AC Immune and WuXi Biologics Expand Strategic Partnership
Plan to accelerate AC Immune’s TDP-43 antibody into clinical development.Contract Pharma Staff 11.10.20
-
Drug Delivery | Drug Development | Trials & Filings
Impel NeuroPharma Submits NDA for INP104 in Acute Migraine
Leverages the company’s Precision Olfactory Delivery technology11.09.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | R&D
Sai Life Sciences to Expand Biology Capabilities
Begins construction of new 75,000 sq. ft. facility in Hyderabad; adding 170 biologists to team.Contract Pharma Staff 10.28.20
-
Breaking News | Clinical Trials
CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin
Phase 2 trial will commence during the first quarter of 2021.Contract Pharma Staff 10.20.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.Contract Pharma Staff 10.14.20
-
APIs | Breaking News | Industry News
NCK A/S Receives CoA for Berubicin API
CNS has a contract with NCK A/S for the large-scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.Contract Pharma Staff 10.01.20
-
Breaking News | cGMP Manufacture | Fill/Finish | Industry News
LSNE, Selecta Biosciences Form Mfg. Pact
LSNE to provide drug substance manufacturing and fill/finish services05.24.17
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
Selexis SA and OSE Immunotherapeutics Enter Pact
Sign agreement for the development of OSE's interleukin receptor 7 antagonist05.24.17
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News | Preclinical Outsourcing | R&D
-
Clinical Trials | CRO News
PSI CRO to Open New Office in Durham
Aims to offer an ideal collaborative setting for both clients and staff in RTP05.10.16
-
Breaking News | Drug Development | Formulation Development | Industry News | Methods Development
Sanofi Licenses Ligand’s Captisol Technology
Will use Captisol in the development and commercialization of cancer therapy SAR-12584407.30.15
-
Breaking News | Clinical Trials | Drug Development | Financial Reports
-
Breaking News | Clinical Trials | Drug Development | Industry News | R&D
Novartis Acquires Spinifex Pharmaceuticals
Expands neuroscience portfolio with novel angiotensin II type 2 receptor antagonist for the treatment of chronic pain07.01.15
-
Breaking News | Financial Reports
